deltatrials
Available EXPANDED_ACCESS NCT05572970

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034), Either as Monotherapy, or as Used in Combination With Zalifrelimab (AGEN1884)

Sponsor: Agenus Inc.

Conditions Cancer
Interventions Balstilimab Zalifrelimab
Updated 5 times since 2022 Last updated: Apr 29, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05572970, this observational or N/A phase trial focuses on Cancer and remains ongoing. Sponsored by Agenus Inc., it has been updated 5 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Nov 2022 – ~Apr 2024 · 17 months · monthly snapshotAvailable~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshotAvailable~May 2025 – present · 14 months · monthly snapshotAvailable

Change History

5 versions recorded

  1. May 2025 — Present [monthly]

    Available

  2. Sep 2024 — May 2025 [monthly]

    Available

  3. Jul 2024 — Sep 2024 [monthly]

    Available

  4. Apr 2024 — Jul 2024 [monthly]

    Available

  5. Nov 2022 — Apr 2024 [monthly]

    Available

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Agenus Inc.
Data source: Agenus Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations